16 June 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

UK Doctor Wins Award for NHS Steriwave Innovation

Mid Yorkshire Teaching NHS Trust's Dr. Stuart Bond Honoured with President's Award for Pioneering Use of Ondine's Steriwave Photodisinfection in the NHS

Ondine Biomedical Inc. (AIM: OBI) announces that Dr. Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust (Mid Yorks), has been awarded the President's Award at the 19th World Congress of the International Photodynamic Association (IPA) in Shanghai. This prestigious award is one of the IPA's highest honours, reserved for individuals whose work is making a transformational impact on healthcare through photodynamic therapy.

The IPA is a global organization dedicated to advancing research, education, and clinical application of photodynamic technologies across medical and biological fields. Dr. Bond was honoured for his pioneering leadership in implementing antimicrobial photodynamic therapy (Ondine's Steriwave^® photodisinfection) in the UK's National Health Service (NHS), a groundbreaking antimicrobial innovation used to prevent surgical site infections (SSI).

Dr. Bond and the teams at Mid Yorks were the first in the NHS to implement pre-surgical photodisinfection using Ondine's Steriwave nasal therapy. Deployed ahead of knee and hip replacement surgeries at Pinderfields and Pontefract hospitals, the approach achieved a remarkable 71% reduction in SSI over a six-month period. This achievement sets a new benchmark for infection prevention and patient safety in the UK, while also delivering significant cost savings to the NHS and greatly improving patient outcomes, all without generating antimicrobial resistance.

Dr. Colin Hopper, President of the IPA said:

"Dr. Bond and his team at Mid Yorks were the first to operationalize photodisinfection within the NHS. Their findings not only demonstrate the clinical value of this approach but also underscore its importance in an era of rising multi-drug resistance, positioning the UK's NHS as a global leader in antibiotic stewardship and patient safety."

Carolyn Cross, CEO of Ondine Biomedical, commented:

"We are absolutely delighted to see Dr. Bond and his exceptional team recognized for their visionary leadership, tireless efforts, and unwavering commitment to improving patient care. Their remarkable achievements not only highlight the Mid York's dedication to antibiotic stewardship but also showcase their willingness to embrace innovative solutions in pursuit of effective, resistance-free alternatives to antibiotics. This recognition by the global photodynamic research and clinical community is truly well deserved."

Ondine's Steriwave is a non-invasive and painless light-activated antimicrobial therapy that destroys harmful pathogens in the nose, a major source of infection, in minutes. The treatment involves applying a proprietary photosensitive agent to each nostril followed by illumination with a specific wavelength of red light. Steriwave is immediately effective against bacteria, viruses, and fungi and does not contribute to antimicrobial resistance. Already improving outcomes and reducing costs at leading hospitals, Steriwave is gaining recognition as a powerful tool in the fight against healthcare-associated infections and antibiotic resistance.

Enquiries:

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave^®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.